8-K: Leap Therapeutics Provides Corporate Update and Clinical Trial Progress

Leap Therapeutics has released an updated corporate presentation highlighting progress in its clinical programs and financial runway.

Summary

• Leap Therapeutics is focused on developing biomarker-targeted antibody therapies for cancer patients.
• The company has two clinical-stage antibody programs: DKN-01 targeting DKK1 and FL-301 targeting CLDN18.2.
• DKN-01 is being evaluated in gastric, colorectal, and endometrial cancers, often in combination with other therapies.
• FL-301 and FL-302 target CLDN18.2, which is overexpressed in some cancers.
• The company's cash runway extends to Q2 2025, with $70 million in cash as of December 31, 2023.
• Multiple clinical trial milestones are expected from two randomized clinical trials.
• DKN-01 has shown promising activity in heavily pretreated esophagogastric cancer patients, with a 40% clinical benefit rate as a monotherapy.
• In combination with paclitaxel, DKN-01 showed a 60% disease control rate and a 25% overall response rate in esophagogastric cancer.
• DKN-01 combined with pembrolizumab in esophagogastric cancer showed improved overall response rate, progression-free survival, and overall survival in DKK1-high patients.
• The DisTinGuish study is a randomized trial of DKN-01 plus tislelizumab and chemotherapy in first-line gastric cancer.
• The DeFianCe study is a randomized phase 2 trial of DKN-01 plus bevacizumab and chemotherapy in second-line colorectal cancer.
• In endometrial cancer, DKN-01 monotherapy showed a 25% overall response rate and a 63% clinical benefit rate in DKK1-high tumors.
• FL-301 is designed to have enhanced tumor-killing efficacy, and FL-302 is a bispecific antibody targeting CLDN18.2 and CD137.
• FL-501 is an anti-GDF15 monoclonal antibody designed to block the immune inhibitory activity of GDF15.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical data and a solid financial position. The company is making good progress in its clinical programs and has a clear strategy.

Positives

• The company has a solid cash position, providing a runway into Q2 2025.
• DKN-01 has demonstrated promising clinical activity in multiple cancer types and treatment settings.
• The biomarker strategy allows for patient stratification and potentially improved treatment outcomes.
• The company has multiple ongoing clinical trials with upcoming milestones.
• FL-301 and FL-302 represent novel approaches to targeting CLDN18.2.
• FL-501 targets GDF15, a novel immune checkpoint with potential in a broad range of cancers.

Negatives

• The company is still in the clinical stage, and there is no guarantee of regulatory approval for any of its drug candidates.
• Some clinical trial results are preliminary and require further validation.
• The company is dependent on collaborations and partnerships for some of its programs.
• The company is operating in a competitive landscape with other companies developing similar therapies.

Risks

• Clinical trial results may not be positive, leading to delays or discontinuation of programs.
• Regulatory approval may not be granted for any of the company's drug candidates.
• The company may need to raise additional capital in the future, which could dilute existing shareholders.
• Competition from other companies in the oncology space could impact the company's market share.
• The company's reliance on collaborations and partnerships could be a risk if those relationships are not maintained.

Future Outlook

The company anticipates multiple milestones from two randomized clinical trials and is focused on advancing its clinical programs.

Industry Context

The company is operating in the competitive oncology space, developing novel antibody therapies targeting specific biomarkers. The focus on biomarker-driven therapies aligns with the industry trend towards personalized medicine.

Comparison to Industry Standards

• The overall response rate of 73% in the mITT population for DKN-01 plus tislelizumab and chemotherapy in first-line gastric cancer is competitive with other anti-PD-1 plus chemotherapy combinations such as Nivolumab (50.4%), Pembrolizumab (47.3%) and Tislelizumab (51.3%).
• The median PFS of 11.3 months in the overall population for DKN-01 plus tislelizumab and chemotherapy in first-line gastric cancer is competitive with other anti-PD-1 plus chemotherapy combinations such as Nivolumab (9.0 months), Pembrolizumab (8.0 months) and Tislelizumab (7.2 months).
• The median OS of 19.5 months in the overall population for DKN-01 plus tislelizumab and chemotherapy in first-line gastric cancer is competitive with other anti-PD-1 plus chemotherapy combinations such as Nivolumab (16.4 months), Pembrolizumab (12.9 months) and Tislelizumab (15.0 months).
• The 30% overall response rate and 93% disease control rate in second-line colorectal cancer with DKN-01 plus chemotherapy and bevacizumab is promising compared to historical data for second-line colorectal cancer treatments.

Stakeholder Impact

• Shareholders may benefit from the positive clinical trial results and the company's strong financial position.
• Employees may be motivated by the company's progress and the potential to develop new cancer therapies.
• Patients may benefit from the development of new and effective cancer treatments.
• Partners may benefit from the company's progress and the potential for commercial success.

Next Steps

• The company will continue to enroll patients in the DisTinGuish and DeFianCe studies.
• The company will report initial data from Part A of the DeFianCe study in Q1 2024.
• The company will report PFS data from Part B of the DeFianCe study in Q2 2024.
• The company will report ORR data from Part C of the DisTinGuish study in Q3 2024.
• The company will report LPI data from Part C of the DisTinGuish study in Q4 2024.

Key Dates

Keywords

DKN-01, FL-301, FL-302, FL-501, cancer, antibody, biomarker, clinical trial, gastric cancer, colorectal cancer, endometrial cancer, DKK1, CLDN18.2, GDF15, immunotherapy